<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84002">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01927549</url>
  </required_header>
  <id_info>
    <org_study_id>CULPRIT-SHOCK1.2</org_study_id>
    <nct_id>NCT01927549</nct_id>
  </id_info>
  <brief_title>Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock</brief_title>
  <acronym>CULPRIT-SHOCK</acronym>
  <official_title>Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Cardiac Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Heart Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the therapies of instant multivessel balloon angioplasty plus stent
      implantation or the balloon angioplasty plus stent implantation of the infarct artery alone
      with any possible graduated later treatment of the other vessels in patients with acute
      myocardial infarction with cardioganic shock.

      The main study hypothesis is to explore if culprit vessel only PCI with potentially
      subsequent staged revascularization in comparison to immediate multivessel revascularization
      by PCI in patients with cardiogenic shock complicating acute myocardial infarction reduces
      the incidence of 30- day mortality and/or severe renal failure requiring renal replacement
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>30-day mortality and/or severe renal failure requiring renal replacement therapy</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of renal replacement therapy</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hemodynamic stabilization</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of catecholamine therapy</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial creatinine-level creatinine-clearance</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU-stay</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial intensive care scoring (SAPS-II score) until stabilization</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement and length of mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death within 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent infarction within 30-days follow-up</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or recurrent infarction at 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for congestive heart failure within 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death/recurrent infarction/rehospitalization for congestive heart failure within 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for repeat revascularization (PCI and/or CABG) within 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak creatine kinase level during hospital stay</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at 6 and 12 months assessed using Euroqol 5D (EQ-5D)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum creatine kinase-MB level</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum troponin level</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent infarction within 12 months follow-up</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">706</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Complications</condition>
  <arm_group>
    <arm_group_label>Immediate multivessel PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter &gt;2 mm with high grade stenoses (&gt;70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Culprit lesion only PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immediate multivessel PCI</intervention_name>
    <arm_group_label>Immediate multivessel PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Culprit Lesion only PCI</intervention_name>
    <arm_group_label>Culprit lesion only PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cardiogenic shock complicating acute myocardial infarction (STEMI or NSTEMI) with
        obligatory:

        I) Planned early revascularization by PCI II) Multivessel coronary artery disease defined
        as more than 70% stenosis in at least 2 major vessels (more than 2 mm diameter) with
        identifiable culprit lesion III)

          1. Systolic blood pressure less than 90 mmHg for more than 30 min or

          2. catecholamines required to maintain pressure more than 90 mmHg during systole and IV)
             Signs of pulmonary congestion V) Signs of impaired organ perfusion with at least one
             of the following criteria

        a) Altered mental status b) Cold, clammy skin and extremities c) Oliguria with urine
        output less than 30 ml/h d) Serum-lactate more than 2.0 mmol/l VI) Informed consent

        Exclusion Criteria:

          -  Resuscitation more than 30 minutes

          -  No intrinsic heart action

          -  Cerebral deficit with fixed dilated pupils (not drug-induced)

          -  Need for primary urgent bypass surgery (to be determined after diagnostic
             angiography)

          -  Single vessel disease

          -  Mechanical cause of cardiogenic shock

          -  Onset of shock more than 12 h

          -  Massive lung emboli

          -  Age more than 90 years

          -  Shock of other cause (bradycardia, sepsis, hypovolemia, etc.)

          -  Other severe concomitant disease with limited life expectancy &lt;6 months

          -  Pregnancy

          -  Known severe renal insufficiency (creatinine clearance &lt;30 ml/kg)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Thiele, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Thiele, MD</last_name>
    <phone>00494515002501</phone>
    <email>holger.thiele@uksh.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd Hasenfuss</last_name>
    </contact>
    <investigator>
      <last_name>Gerd Hasenfuss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig - Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Schuler, MD</last_name>
      <phone>00493418651428</phone>
      <email>gerhard.schuler@med.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Georg Fuernau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerhard Schuler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Thiele</last_name>
      <email>holger.thiele@uksh.de</email>
    </contact>
    <contact_backup>
      <last_name>Renate Domeier</last_name>
      <email>renate.domeier@uksh.de</email>
    </contact_backup>
    <investigator>
      <last_name>Steffen Desch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Holger Thiele</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Mortensen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://studien.herzinfarktforschung.de/CulpritShock/login?ReturnUrl=%2fculpritshock</url>
    <description>eCRF and randomization site</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Holger Thiele</investigator_full_name>
    <investigator_title>Coordinator</investigator_title>
  </responsible_party>
  <keyword>cardiogenic shock</keyword>
  <keyword>infarction</keyword>
  <keyword>multivessel coronary artery disease</keyword>
  <keyword>angioplasty</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
